share_log

Q2 2023 Earnings Estimate for Catalent, Inc. Issued By Jefferies Financial Group (NYSE:CTLT)

Q2 2023 Earnings Estimate for Catalent, Inc. Issued By Jefferies Financial Group (NYSE:CTLT)

杰富瑞金融集团(纽约证券交易所代码:CTLT)发布的Catalent, Inc.2023年第二季度收益预期
Defense World ·  2023/01/26 02:36

Catalent, Inc. (NYSE:CTLT – Get Rating) – Analysts at Jefferies Financial Group upped their Q2 2023 EPS estimates for shares of Catalent in a report released on Tuesday, January 24th. Jefferies Financial Group analyst D. Windley now expects that the company will earn $0.71 per share for the quarter, up from their previous estimate of $0.70. The consensus estimate for Catalent's current full-year earnings is $2.93 per share. Jefferies Financial Group also issued estimates for Catalent's Q3 2023 earnings at $0.86 EPS.

Catalent,Inc.(纽约证券交易所代码:CTLT-GET Rating)-在1月24日星期二发布的一份报告中,杰富瑞金融集团的分析师上调了对Catalent股票2023年第二季度每股收益的预期。杰富瑞金融集团分析师D.Windley现在预计,该公司本季度每股收益为0.71美元,高于此前预期的0.70美元。对Catalent目前全年收益的普遍预期为每股2.93美元。杰富瑞金融集团还发布了对Catalent 2023年第三季度每股收益的估计为0.86美元。

Get
到达
Catalent
Catalent
alerts:
警报:

A number of other equities analysts also recently issued reports on CTLT. TheStreet downgraded shares of Catalent from a "b-" rating to a "c+" rating in a research note on Friday, October 28th. Bank of America cut shares of Catalent from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $125.00 to $60.00 in a report on Wednesday, November 2nd. Argus cut shares of Catalent from a "buy" rating to a "hold" rating in a report on Monday, November 7th. Royal Bank of Canada cut their price objective on shares of Catalent from $125.00 to $73.00 and set an "outperform" rating for the company in a report on Wednesday, November 2nd. Finally, Morgan Stanley cut their price objective on shares of Catalent from $120.00 to $81.00 and set an "overweight" rating for the company in a report on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $92.40.

其他一些股票分析师最近也发布了关于CTLT的报告。华尔街在10月28日星期五的一份研究报告中将Catalent的股票评级从“b-”下调至“c+”。美国银行在11月2日(周三)的一份报告中将卡特伦特的股票评级从买入下调至中性,并将该股的目标价从125.00美元下调至60美元。在11月7日星期一的一份报告中,Argus将Catalent的股票评级从“买入”下调至“持有”。11月2日,加拿大皇家银行在一份报告中将卡特伦特股票的目标价从125.00美元下调至73.0美元,并为该公司设定了“跑赢大盘”的评级。最后,摩根士丹利在11月3日周四的一份报告中将加泰罗兰股票的目标价从120.00美元下调至81.00美元,并为该公司设定了“增持”评级。一位研究分析师对该股的评级为卖出,三位分析师给出了持有评级,五位分析师给出了该公司股票的买入评级。根据MarketBeat.com的数据,该股目前的普遍评级为持有,平均目标价为92.40美元。

Catalent Price Performance

催化剂的性价比

Shares of CTLT stock opened at $50.16 on Wednesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.86 and a quick ratio of 2.08. The company has a market capitalization of $9.03 billion, a P/E ratio of 21.44, a P/E/G ratio of 3.63 and a beta of 1.24. The company's 50-day simple moving average is $46.33 and its two-hundred day simple moving average is $71.89. Catalent has a one year low of $40.69 and a one year high of $115.33.
周三,CTLT的股票开盘报50.16美元。该公司的债务权益比为0.87,流动比率为2.86,速动比率为2.08。该公司市值为90.3亿美元,市盈率为21.44倍,市盈率为3.63倍,贝塔系数为1.24。该公司50日简单移动均线切入位在46.33美元,200日简单移动均线切入位在71.89美元。Catalent的一年低点为40.69美元,一年高位为115.33美元。

Catalent (NYSE:CTLT – Get Rating) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $0.25 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by ($0.24). The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a return on equity of 12.55% and a net margin of 8.83%.

Catalent(NYSE:CTLT-GET Rating)最近一次公布季度收益数据是在11月1日星期二。该公司公布本季度每股收益为0.25美元,低于分析师普遍预期的0.49美元(0.24美元)。该公司本季度营收为10.2亿美元,高于分析师预期的10.6亿美元。Catalent的股本回报率为12.55%,净利润率为8.83%。

Insiders Place Their Bets

内部人士下注

In other Catalent news, insider Ricky Hopson sold 643 shares of the business's stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $49.36, for a total transaction of $31,738.48. Following the completion of the transaction, the insider now owns 16,452 shares in the company, valued at approximately $812,070.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Manja Boerman sold 780 shares of the business's stock in a transaction on Monday, December 5th. The shares were sold at an average price of $51.70, for a total value of $40,326.00. Following the completion of the sale, the insider now directly owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ricky Hopson sold 643 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $49.36, for a total transaction of $31,738.48. Following the completion of the sale, the insider now directly owns 16,452 shares of the company's stock, valued at $812,070.72. The disclosure for this sale can be found here. Insiders sold 3,874 shares of company stock worth $233,414 in the last 90 days. Corporate insiders own 0.58% of the company's stock.

在加泰罗尼亚的其他消息中,内部人士里奇·霍普森在1月23日星期一的一笔交易中出售了643股该公司的股票。这些股票的平均价格为49.36美元,总成交额为31,738.48美元。交易完成后,这位内部人士现在拥有该公司16,452股股票,价值约812,070.72美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在此超链接。在相关新闻中,内部人士Manja Boerman在12月5日星期一的一次交易中出售了780股该公司的股票。这些股票的平均价格为51.70美元,总价值为40,326.00美元。出售完成后,这位内部人士现在直接持有该公司15,860股股票,价值819,962美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。此外,内部人士里奇·霍普森在1月23日星期一的一次交易中出售了643股该公司的股票。这些股票的平均价格为49.36美元,总成交额为31,738.48美元。出售完成后,这位内部人士现在直接持有该公司16,452股股票,价值812,070.72美元。关于这次销售的披露可以找到这里。在过去的90天里,内部人士出售了3874股公司股票,价值233,414美元。企业内部人士持有该公司0.58%的股份。

Institutional Investors Weigh In On Catalent

机构投资者看好Catalent

A number of institutional investors and hedge funds have recently bought and sold shares of CTLT. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Catalent by 22.5% during the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,043 shares of the company's stock worth $326,000 after acquiring an additional 558 shares during the period. US Bancorp DE grew its position in Catalent by 1.4% during the third quarter. US Bancorp DE now owns 19,237 shares of the company's stock worth $1,392,000 after buying an additional 272 shares during the period. Mitsubishi UFJ Trust & Banking Corp grew its position in Catalent by 12.0% during the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 90,954 shares of the company's stock worth $9,759,000 after buying an additional 9,723 shares during the period. Illinois Municipal Retirement Fund grew its position in Catalent by 88.1% during the second quarter. Illinois Municipal Retirement Fund now owns 6,028 shares of the company's stock worth $647,000 after buying an additional 2,824 shares during the period. Finally, Private Advisor Group LLC grew its position in Catalent by 98.5% during the second quarter. Private Advisor Group LLC now owns 5,870 shares of the company's stock worth $630,000 after buying an additional 2,913 shares during the period. 99.38% of the stock is owned by hedge funds and other institutional investors.

一些机构投资者和对冲基金最近买卖了CTLT的股票。东京海上资产管理公司在第二季度增持了22.5%的Catalent股票。东京海上资产管理有限公司在此期间增持了558股,目前持有该公司3,043股股票,价值326,000美元。US Bancorp DE在第三季度增加了1.4%的Catalent头寸。US Bancorp DE现在拥有19,237股该公司股票,价值1,392,000美元,在此期间又购买了272股。三菱UFJ信托银行(Mitsubishi UFJ Trust&Banking Corp)第二季度在Catalent的头寸增加了12.0%。三菱UFJ信托银行(Mitsubishi UFJ Trust&Banking Corp)目前持有90,954股该公司股票,价值9,759,000美元,在此期间又购买了9,723股。伊利诺伊市退休基金在第二季度将其在Catalent的头寸增加了88.1%。伊利诺伊州市政退休基金现在拥有该公司6,028股股票,价值647,000美元,在此期间又购买了2,824股。最后,Private Advisor Group LLC在第二季度将其在Catalent的头寸增加了98.5%。Private Advisor Group LLC在此期间又购买了2,913股,现在拥有5870股该公司股票,价值630,000美元。99.38%的股票由对冲基金和其他机构投资者持有。

Catalent Company Profile

Catalent公司简介

(Get Rating)

(获取评级)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Catalent公司及其子公司在全球范围内开发和制造药物、基于蛋白质的生物制剂、细胞和基因疗法以及消费者保健产品的解决方案。软凝胶和口腔技术部门提供用于一系列客户产品的软胶囊的配方、开发和制造服务,如处方药、非处方药、膳食补充剂、单位剂量化妆品和动物保健药物制剂。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on Catalent (CTLT)
  • AMD Is Still One Of The Best Semiconductor Stocks Out There
  • Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
  • Is The Bottom In For Cyber-Security Stocks?
  • Union Pacific, Norfolk Southern Pull into Buying Zone
  • Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
  • 免费获取StockNews.com关于Catalent的研究报告(CTLT)
  • AMD仍是市面上最好的半导体股票之一
  • 两大股利大王:强生还是雅培?
  • 网络安全类股已经见底了吗?
  • 联合太平洋,诺福克南方进入购买区
  • 柔顺治疗公司的差距增加了34%:未来还会有更多的好处吗?

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Catalent Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Catalent和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发